Compare Sinar Eka Selaras Tbk. (ERAL) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sinar Eka Selaras Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Sinar Eka Selaras Tbk. trades at Rp320 (market cap 1.67T, 6.96M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Sinar Eka Selaras Tbk. is far larger — about 16× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| ERAL | SCPI | |
|---|---|---|
Market Cap | 1.67T | 104.4B |
Volume | 6.96M | — |
Lot | 69.56K | — |
Turnover | 2.22B | — |
Average Price | 319.06 | — |
Value | 2.22B | — |
Indicative Equilibrium Price | 320 | — |
Indicative Equilibrium Volume | 1.31K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sinar Eka Selaras Tbk.
PT Sinar Eka Selaras Tbk (the “Company”) was established in Indonesia based on Notarial Deed No. 12 of Myra Yuwono, S.H., dated March 13, 2009. PT Erajaya Swasembada Tbk, an entity incorporated in Indonesia, is the parent company of the Company. PT Eralink International, an entity incorporated inIndonesia, is the ultimate parent of the Company.
Read more on ERAL →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
